150 related articles for article (PubMed ID: 31794609)
21. CAR-T: trailblazing the path from clinical development to the clinic.
Butera S
Gene Ther; 2018 Jun; 25(3):163-164. PubMed ID: 29686331
[No Abstract] [Full Text] [Related]
22. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
[TBL] [Abstract][Full Text] [Related]
23. CAR-T field booms as next-generation platforms attract big players.
Morrison C
Nat Biotechnol; 2015 Jun; 33(6):571-2. PubMed ID: 26057954
[No Abstract] [Full Text] [Related]
24. Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.
Prommersberger S; Jetani H; Danhof S; Monjezi R; Nerreter T; Beckmann J; Einsele H; Hudecek M
Curr Res Transl Med; 2018 May; 66(2):37-38. PubMed ID: 29655962
[No Abstract] [Full Text] [Related]
25. Gut decisions in CAR T cell therapy.
Attwaters M
Nat Cancer; 2023 Dec; 4(12):1638. PubMed ID: 38102347
[No Abstract] [Full Text] [Related]
26. Beware of the CAR-T Hitches.
Ladika S
Manag Care; 2019 May; 28(5):35-37. PubMed ID: 31188109
[TBL] [Abstract][Full Text] [Related]
27. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy hits the market.
Boyer MW
Immunotherapy; 2018 Aug; 10(11):911-912. PubMed ID: 30149765
[No Abstract] [Full Text] [Related]
29. A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy.
Tessema FA; Darrow JJ
J Law Med Ethics; 2017 Dec; 45(4):692-697. PubMed ID: 30027797
[No Abstract] [Full Text] [Related]
30. Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.
Cooper LJ
Cancer Gene Ther; 2015 Mar; 22(2):64-6. PubMed ID: 25675874
[No Abstract] [Full Text] [Related]
31. Effectiveness of chimeric antigen receptor T cells may be impaired by prior chemotherapy.
Printz C
Cancer; 2018 Jul; 124(14):2877. PubMed ID: 29975408
[No Abstract] [Full Text] [Related]
32. Driving cars to the clinic for solid tumors.
Castellarin M; Watanabe K; June CH; Kloss CC; Posey AD
Gene Ther; 2018 Jun; 25(3):165-175. PubMed ID: 29880908
[TBL] [Abstract][Full Text] [Related]
33. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
34. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
35. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.
Wang X; Rivière I
Cancer Gene Ther; 2015 Mar; 22(2):85-94. PubMed ID: 25721207
[TBL] [Abstract][Full Text] [Related]
36. [CAR-T cell development and other gene therapy: Everything is not so easy].
Dalle JH; Baudoux E; Caillat-Zucman S; Colledani F; Pereira M; Bruno B; Nguyen S; Robin M; Rubio MT; Bay JO
Bull Cancer; 2020 Apr; 107(4):408-409. PubMed ID: 32334675
[No Abstract] [Full Text] [Related]
37. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
38. Driving an improved CAR for cancer immunotherapy.
Huang X; Yang Y
J Clin Invest; 2016 Aug; 126(8):2795-8. PubMed ID: 27454296
[TBL] [Abstract][Full Text] [Related]
39. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
40. CAR T-cell therapy: opportunities and challenges.
Zhang W
Immunotherapy; 2016; 8(3):245-7. PubMed ID: 26860858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
